Seeyond Exact Sciences Corp Transaction History

Seeyond

$1.03 Billion
Q4 2022

A detailed history of Seeyond transactions in Exact Sciences Corp stock. As of the latest transaction made, Seeyond holds 3,303 shares of EXAS stock, worth $224,901. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,303

Previous 12,092 72.68%

Holding current value

$224,901

Previous $392,000 58.42%

% of portfolio

0.02%

Previous 0.05%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$30.35 - $53.15 $266,746 - $467,135	-8,789 Reduced 72.68%	3,303 $163,000
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $232,997 - $359,808	7,288 Added 151.71%	12,092 $392,000
Q2 2022 Aug 12, 2022	SELL	$35.61 - $76.23 $3,454 - $7,394	-97 Reduced 1.98%	4,804 $189,000
Q1 2022 May 13, 2022	SELL	$57.56 - $82.54 $8,461 - $12,133	-147 Reduced 2.91%	4,901 $342,000
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $277,747 - $385,705	3,831 Added 314.79%	5,048 $392,000
Q3 2021 Nov 12, 2021	SELL	$90.24 - $124.05 $1,173 - $1,612	-13 Reduced 1.06%	1,217 $116,000
Q2 2021 Aug 13, 2021	BUY	$93.66 - $139.27 $561 - $835	6 Added 0.49%	1,230 $152,000
Q1 2021 May 14, 2021	SELL	$116.57 - $155.01 $209,592 - $278,707	-1,798 Reduced 59.5%	1,224 $161,000
Q4 2020 Feb 12, 2021	BUY	$99.61 - $142.12 $178,401 - $254,536	1,791 Added 145.49%	3,022 $400,000
Q3 2020 Nov 12, 2020	SELL	$72.92 - $102.01 $139,933 - $195,757	-1,919 Reduced 60.92%	1,231 $126,000
Q2 2020 Aug 13, 2020	BUY	$55.75 - $92.75 $119,639 - $199,041	2,146 Added 213.75%	3,150 $274,000
Q1 2020 May 14, 2020	SELL	$37.9 - $104.44 $189 - $522	-5 Reduced 0.5%	1,004 $124,000
Q2 2019 Aug 13, 2019	BUY	$89.51 - $118.04 $90,315 - $119,102	1,009 New	1,009 $119,000

Others Institutions Holding EXAS

# of Institutions

610

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seeyond, based on Form 13F filings with the SEC.

News

Stay updated on Seeyond with notifications on news.

Account